Form 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of December 2009

Commission File Number: 001-31368

SANOFI-AVENTIS

(Translation of registrant’s name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x                    Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨                                No x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  82-                

In December 2009, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.   

Description

Exhibit 99.1    Press release dated December 10, 2009: Sanofi-aventis and US biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases.
Exhibit 99.2    Press release dated December 16, 2009: Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections.
Exhibit 99.3    Press release dated December 16, 2009: Sanofi-aventis Board of Directors of December 16, 2009.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: December 17, 2009                         SANOFI-AVENTIS
    By               /S/      John Felitti                  
      Name:   John Felitti
      Title:  

Director, U.S. & International

Securities Law

 

3

Exhibit Index

 

Exhibit No.   

Description

Exhibit 99.1    Press release dated December 10, 2009: Sanofi-aventis and US biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases.
Exhibit 99.2    Press release dated December 16, 2009: Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections.
Exhibit 99.3    Press release dated December 16, 2009: Sanofi-aventis Board of Directors of December 16, 2009.

 

4